NZ760019B2 - Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof - Google Patents
Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof Download PDFInfo
- Publication number
- NZ760019B2 NZ760019B2 NZ760019A NZ76001917A NZ760019B2 NZ 760019 B2 NZ760019 B2 NZ 760019B2 NZ 760019 A NZ760019 A NZ 760019A NZ 76001917 A NZ76001917 A NZ 76001917A NZ 760019 B2 NZ760019 B2 NZ 760019B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- pfsh
- subunit
- fusion protein
- pfsha
- pfshß
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 60
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 55
- 238000003975 animal breeding Methods 0.000 claims abstract description 19
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract description 17
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract description 17
- 238000005411 Van der Waals force Methods 0.000 claims abstract description 10
- 241001465754 Metazoa Species 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 44
- 230000012173 estrus Effects 0.000 claims description 37
- 241000283690 Bos taurus Species 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- 206010042573 Superovulation Diseases 0.000 claims description 16
- 241000283707 Capra Species 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 241001494479 Pecora Species 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 10
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000013604 expression vector Substances 0.000 claims description 9
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 241000283073 Equus caballus Species 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 230000001850 reproductive effect Effects 0.000 claims description 6
- 102000035824 beta Subunit Follicle Stimulating Hormone Human genes 0.000 claims description 5
- 108010081485 beta Subunit Follicle Stimulating Hormone Proteins 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 claims description 5
- 239000000710 homodimer Substances 0.000 claims description 5
- 108020004705 Codon Proteins 0.000 claims description 4
- 239000013599 cloning vector Substances 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 238000005457 optimization Methods 0.000 claims description 4
- 230000001131 transforming effect Effects 0.000 claims description 4
- 238000010367 cloning Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract description 78
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract description 78
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract description 75
- 239000003814 drug Substances 0.000 abstract description 24
- 229940079593 drug Drugs 0.000 abstract description 22
- 210000002966 serum Anatomy 0.000 abstract description 19
- 102000006771 Gonadotropins Human genes 0.000 abstract description 6
- 108010086677 Gonadotropins Proteins 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 6
- 239000002622 gonadotropin Substances 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000007721 medicinal effect Effects 0.000 abstract description 3
- 230000000816 effect on animals Effects 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 150000001413 amino acids Chemical group 0.000 description 21
- 239000000243 solution Substances 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 11
- 210000002257 embryonic structure Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 8
- 230000001817 pituitary effect Effects 0.000 description 8
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 7
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 241000282887 Suidae Species 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 102000035118 modified proteins Human genes 0.000 description 6
- 108091005573 modified proteins Proteins 0.000 description 6
- 229940047883 porcine follicle stimulating hormone Drugs 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 241000283086 Equidae Species 0.000 description 4
- 241000009328 Perro Species 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 210000004237 neck muscle Anatomy 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- VJGGHXVGBSZVMZ-QIZQQNKQSA-N Cloprostenol Chemical compound C([C@H](O)\C=C\[C@@H]1[C@H]([C@@H](O)C[C@H]1O)C\C=C/CCCC(O)=O)OC1=CC=CC(Cl)=C1 VJGGHXVGBSZVMZ-QIZQQNKQSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000002863 seminiferous tubule Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000013449 Capto Q chromatography Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283087 Equus Species 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 229960004409 cloprostenol Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940045662 porcine thyroid Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102220315697 rs1553622313 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
Abstract
Two long-acting recombinant porcine FSH (follicle-stimulating hormone) fusion proteins, comprising pFSH-Fc-1 and pFSH-Fc-2. a subunit/ß subunit is directly or indirectly fused on an Fc fragment by means of a connecting component; the ß subunit/a subunit is combined with the a subunit/ß subunit by means of a Van der Waals force or the connecting component. The porcine FSH fusion proteins can be prepared by an eukaryotic expression system based on a gene engineering technology. The two porcine FSH fusion proteins have a good medicinal effect and have a longer half-life period as compared with that of a natural porcine FSH; the two porcine FSH fusion proteins do not generate an undesirable effect on animals and can replace pregnant mare serum gonadotropin (PMSG) to be used in animal breeding production. The two porcine FSH fusion proteins can be used for preparation of medicines in the field of animal breeding.
Description
Two long-acting recombinant porcine FSH (follicle-stimulating hormone) fusion proteins, comprising pFSH-Fc-1 and pFSH-Fc-2. a subunit/ß subunit is directly or indirectly fused on an Fc fragment by means of a connecting component; the ß subunit/a subunit is combined with the a subunit/ß subunit by means of a Van der Waals force or the connecting component. The porcine FSH fusion proteins can be prepared by an eukaryotic expression system based on a gene engineering technology. The two porcine FSH fusion proteins have a good medicinal effect and have a longer half-life period as compared with that of a natural porcine FSH; the two porcine FSH fusion proteins do not generate an undesirable effect on animals and can replace pregnant mare serum gonadotropin (PMSG) to be used in animal breeding production. The two porcine FSH fusion proteins can be used for preparation of medicines in the field of animal breeding.
NZ 760019 B2 Long-acting Recombinant Porcine FSH Fusion Protein and Preparation Method and Application Thereof Technical Field The present invention relates to the field of biomedicine and animal breeding technology, in particular to a long-acting recombinant porcine FSH fusion protein and a preparation method and application thereof.
Background Art Porcine follicle-stimulating hormone (pFSH) is a gonadotropin secreted by the porcine anterior pituitary, and which is formed by an a subunit and a ß subunit that are non-covalently linked; wherein, the a subunit is highly conserved and identical to the a subunit of Porcine Luteinizing Hormone (pLH) and Porcine Thyroid Stimulating Hormone (pTSH); and the ß subunit differs, which mainly determines the functional specificity of FSH. pFSH can promote the growth and maturation of sow endometrium, ovary and follicles; promote the synthesis and secretion of estrogen; and induce the development of boar seminiferous tubules and maintain spermatogenesis. pFSH is commonly used in the field of animal breeding for the synchronization of estrus, superovulation, embryo transplantation, and treatment of ovarian diseases in female animals. Studies show that the effect of porcine FSH for superovulation of cattle and sheep is better than that of FSH of cattle and sheep, and thus, pFSH is of great value in livestock production and economic animal breeding.
At present, related patents and articles report the expression of FSH fusion proteins, but most of them are related to the recombinant expression and application of a human FSH. The use of the human FSH in the field of animal breeding has also achieved some success.
However, although humans and domestic animals belong to mammals, there are still large species differences in protein sequences (the human FSH and porcine FSH have a homology of 73% in term of the amino acid sequence of the a subunit, a homology of 93% in term of ß subunit, and a homology of 73% in term of Fc fragment). If the human recombinant FSH is used in animals for a long time, the animal’s immune system will recognize the human recombinant FSH and induce the production of antibodies (including neutralizing antibodies), which specifically bind to the receptor binding site of the animal FSH, thereby blocking the biological activity of the drug, and resulting in the lower and lower bioavailability of the human FSH in animals, which limits the application of the human FSH in animals, especially in economic animals such as pig, cattle and sheep that need to use FSH for a long time. This is one of the reasons why the currently marketed human recombinant FSH is not used in the field of animal breeding.
Currently, commercial FSH products on the market mainly include FSH extracted from porcine pituitary and pregnant mare serum gonadotropin (PMSG). Porcine pituitary FSH, such as Folltropin-V (Canada), has a short half-life (5 hours) and requires frequent administration, resulting in high cost of feeding and management for terminal customers.
Furthermore, it is difficult to separate porcine FSH from LH when purified from porcine pituitary tissue, and the difficult purification and the low productivity greatly limit the practical applications of porcine FSH. PMSG is a glycoprotein hormone secreted by the chorioallantoic membrane cells of the placenta of an animal of genus Equus, has both FSH (high) and LH (low) activities, and has the effect of promoting the reproductive function of ovaries and testes of animals. In the field of animal breeding, PMSG is often used for inducing synchronization of estrus and superovulation of female animals, and treating reproductive disorders and ovarian insufficiency in female animals; promoting the development of seminiferous tubules and spermatogenesis in male animals. However, since PMSG molecules contain a relatively high amount of hexose and sialic acid, and have a long half-life in animals (120h), when used in animals for superovulation, it is easy to cause various adverse effects in dams, such as ovarian cysts, early degradation of the embryo at the beginning of pregnancy. Furthermore, commercial PMSG is extracted and purified from the serum of pregnant horses; when used in other animals, antibodies will be produced, and PMSG has certain immunogenicity and cannot be used for a long time. In addition, PMSG is prepared by collecting serum from pregnant horses and this often causes abortion of pregnant horses and death of fetal horses due to excessive blood collection, which is inconformity with animal ethics.
Therefore, on the basis that human FSH is not suitable for animals, porcine pituitary FSH requires frequent administration, and PMSG is prone to cause adverse effects, there is a need for a long-acting animal-source FSH in the breeding field of animals, especially economic animals.
Summary of the Invention The purpose of the present invention is to provide a novel long-acting recombinant porcine FSH fusion protein and a preparation method and application thereof.
The concept of the present invention is as follows: Fc fusion protein technology is one of the most widely used and stable technologies in the development of long-acting protein drugs, and FSH is fused with Fc by genetic engineering technology to produce a novel recombinant protein FSH-Fc. Not only the high biological activity of FSH can be retained, but also a longer half-life can be obtained. At the same time, the obtained recombinant protein has high purity, relatively uniform quality, no LH and high safety factor. The use of mammalian expression systems, especially Chinese hamster ovary cells (CHO) for the expression of recombinant proteins, provides protein molecules that are closest to nature molecules in terms of molecular structure, physicochemical properties, and biological functions.
For the purposes of the present invention, the long-acting recombinant porcine FSH fusion proteins of the present invention comprise fusion proteins pFSH-Fc-1 and pFSH-Fc-2, wherein a subunit of the porcine FSH fusion protein pFSH-Fc-1 is directly or indirectly fused with the Fc fragment by means of a linking component, and ß subunit of the porcine FSH fusion protein pFSH-Fc-1 binds with the a subunit by means of a Van der Waals force or a linking component; and ß subunit of the porcine FSH fusion protein pFSH-Fc-2 is directly or indirectly fused with the Fc fragment by means of a linking component, and a subunit of the porcine FSH fusion protein pFSH-Fc-2 binds with the ß subunit by means of a Van der Waals force or a linking component..
The porcine FSH fusion protein comprises two peptide chains conforming to the following equation: (pFSHß:pFSHa-L-Fc) or (pFSHa:pFSHß-L-Fc) , wherein the pFSHß refers to a ß subunit of the porcine FSH with signal peptide removed; the colon represents the relationship that the porcine FSH ß subunit and the a subunit are linked by means of a Van der Waals force; pFSHa refers to an a subunit of the porcine FSH with signal peptide removed; L represents the linking relationship between the pFSHa or pFSHß subunit and the Fc fragment; Fc refers to the Fc fragment of the immunoglobulin, or a mutant thereof; the subscript 2 outside of the parenthesis represents that the porcine FSH fusion protein is a divalent homodimer.
In an aspect, the present invention provides a long-acting recombinant porcine FSH fusion protein pFSH-Fc-1, wherein the pFSH-Fc-1 comprises two peptide chains and conforms to the equation (pFSHß:pFSHa-L-Fc)2, wherein the pFSHß refers to a ß subunit of the porcine FSH with signal peptide removed; the colon represents that the porcine FSH ß subunit and the a subunit are linked by means of a Van der Waals force; pFSHa refers to an a subunit of the porcine FSH with signal peptide removed; L represents the linking relationship between the pFSHa subunit and the Fc fragment; Fc refers to a Fc fragment of an immunoglobulin; the subscript 2 outside of the parenthesis represents that the pFSH-Fc-1 is a divalent homodimer, wherein the amino sequence of the pFSHa-L-Fc is shown in SEQ ID NO: 6, and the amino sequence of the pFSHß is shown in SEQ ID NO:3.
In an aspect, the present invention provides a long-acting recombinant porcine FSH fusion protein pFSH-Fc-2, wherein the pFSH-Fc-2 comprises two peptide chains and conforms to the equation (pFSHa:pFSHß-L-Fc) , wherein the pFSHß refers to a ß subunit of the porcine FSH with signal peptide removed; the colon represents that the porcine FSH ß subunit and the a subunit are linked by means of a Van der Waals force; pFSHa refers to an a subunit of the porcine FSH with signal peptide removed; L represents the linking relationship between the pFSHß subunit and the Fc fragment; Fc refers to a Fc fragment of an immunoglobulin; the subscript 2 outside of the parenthesis represents that pFSH-Fc-2 is a divalent homodimer; wherein the amino sequence of the pFSHß-L-Fc is shown in SEQ ID NO: 8, and the amino sequence of the pFSHa is shown in SEQ ID NO:1.
The amino acid sequence of the pFSHa is represented by SEQ ID NO: 1, or the pFSHa is composed of an amino acid sequence having a homology of 90% or more with SEQ ID NO: 1 and an activity equivalent to that of SEQ ID NO: 1.
The amino acid sequence of the pFSHß is represented by SEQ ID NO: 3, or the pFSH ß is composed of an amino acid sequence having a homology of 90% or more with SEQ ID NO: 3 and an activity equivalent to that of SEQ ID NO: 3.
The Fc comprises a hinge region as well as CH2 and CH3 regions of an immunoglobulin.
The immunoglobulin is derived from human, pig, cattle, sheep, horse or dog.
Immunoglobulins are classified into IgG, IgM, IgA, IgD, and IgE, and each type of immunoglobulin includes various subtypes, such as IgG1, IgG2, IgG3, and IgG4.
The Fc mutant refers to a Fc variant comprising amino acid mutation at one or more sites in the Fc fragment, and includes a human IgG2 Fc variant comprising a human IgG2 hinge region, a CH2 region and a CH3 region, with a mutation Pro331Ser.
Preferably, the Fc is derived from a porcine immunoglobulin, i.e., pFc, and comprises the hinge region, CH2 and CH3 regions of the porcine immunoglobulin. The amino acid sequence of the pFc is represented by SEQ ID NO: 5, or the pFc is composed of an amino acid sequence having a homology of 80% or more with SEQ ID NO: 5 and an activity equivalent to that of SEQ ID NO: 5.
The pFSHa or pFSHß subunit is linked to the Fc directly or by a linker, preferably by a linker.
Wherein, the linker is a flexible polypeptide consisting of 2 to 20 flexible amino acid selected from at least one of Gly, Ser, Ala and Thr; Preferably, the linker is (Gly-Gly-Gly-Gly-Ser) , wherein n is an integer between 2 and , more preferably n is 3.
Preferably, the pFSHa-L-Fc is: i) a protein constituted by the amino acid sequence as represented by SEQ ID No. 6; or ii) a protein derived from i), which is consisted of an amino acid sequence having a function equivalent to that of SEQ ID No. 6 and obtained from the amino acid sequence as represented by SEQ ID No. 6 by substitution, deletion and/or addition of one or more amino acids; or iii) a protein constituted by an amino acid sequence having a homology of 90% or more with the amino acid sequence as represented by SEQ ID No. 6 and having a function equivalent to that of SEQ ID No. 6.
Preferably, the pFSHß-L-Fc is: iv) a protein constituted by the amino acid sequence as represented by SEQ ID No. 8; or v) a protein derived from iv), which is consisted of an amino acid sequence having a function equivalent to that of SEQ ID No. 8 and obtained from the amino acid sequence as represented by SEQ ID No. 8 by substitution, deletion and/or addition of one or more amino acids; or vi) a protein constituted by an amino acid sequence having a homology of 90% or more with the amino acid sequence as represented by SEQ ID No. 8 and having a function equivalent to SEQ ID No. 8.
The present invention also provides an expression cassette, expression vector, cloning vector, engineering bacteria or transgenic cell line, comprising a nucleic acid encoding the fusion protein described above.
The long-acting recombinant porcine FSH fusion protein of the present invention can be prepared as follows: artificially synthesizing genes encoding pFSHa, pFSHß, pFSHa-L-Fc and pFSHß-L-Fc, performing codon optimization, and cloning the optimized genes into eukaryotic expression vectors, respectively; simultaneously transforming the pFSHa recombinant vector and pFSHß-L-Fc recombinant vector into eukaryotic cells, and expressing in eukaryotic cells, and isolating and purifying the target protein; simultaneously transforming the pFSHß recombinant vector and pFSHa-L-Fc recombinant vector into eukaryotic cells, and expressing in eukaryotic cells, and isolating and purifying the target protein.
The eukaryotic expression vector includes, but is not limited to, pcDNA3.1, and the eukaryotic cells include, but are not limited to, 293 and CHO cells.
The present invention also provides the use of the above-mentioned long-acting recombinant porcine FSH fusion protein for the preparation of a medicament for promoting animal breeding (including synchronization of estrus, superovulation and the like) and for treating a reproductive-related disease in animals. Wherein the animal includes, but is not limited to, pig, cattle, sheep, horse or dog; preferably pig.
The present invention further provides a medicament for promoting animal breeding (including synchronization of estrus, superovulation and the like) and for treating a reproductive-related disease of an animal prepared from the above-mentioned long-acting recombinant porcine FSH fusion protein.
The invention also provides the use of the above-mentioned long-acting recombinant porcine FSH fusion protein in the field of animal breeding.
Modified proteins, including two fusion proteins pFSH-Fc-1, pFSH-Fc-2 or porcine FSH which has been glycosylated, PEGylated, acetylated or bound to BSA and the like are all within the scope of the present invention.
The engineered proteins, including two fusion proteins pFSH-Fc-1, pFSH-Fc-2 or fusion proteins that are constituted by fusing porcine FSH protein with porcine Fc or other proteins, without changes in the activity of porcine FSH protein, are all within the scope of the present invention.
In an aspect, the present invention provides a composition comprising a fusion protein as described herein, an expression cassette as described herein, an expression vector as described herein, a cloning vector as described herein, and/or a CHO cell as described herein, together with an acceptable carrier, diluent, or excipient.
In an aspect, the present invention provides a method of promoting animal breeding in an animal, wherein the method comprises administering a fusion protein as described herein and/or a composition as described herein to the animal, wherein the animal is a pig, a cattle, a sheep, a horse or a dog; preferably a pig.
In an aspect, the present invention provides a method of synchronizing estrus and superovulation in an animal, the method comprising the step of administering a fusion protein as described herein and/or a composition as described herein, to thereby synchronize estrus and superovulation in the animal, wherein the animal is a pig, a cattle, or a goat.
In an aspect, the present invention provides a method of treating a reproductive-related disease in an animal, wherein the method comprises: administering a fusion protein as described herein and/or a composition as described herein to the animal, wherein the animal is pig, a cattle, a sheep, a horse or a dog; preferably pig.
In an aspect, the present invention provides a method of treating anestrus in a pig, the method comprising the step of administering a fusion protein as described herein and/or a composition according as described herein, to thereby treat anestrus in the pig.
Compared with the prior art, the present invention has the following advantages: (I) The long-acting recombinant porcine FSH fusion protein and/or porcine FSH protein, and the derived proteins or modified proteins thereof provided by the present invention, have a half-life of about 60 h, which is higher than that of porcine pituitary FSH, but lower than that of PMSG. They do not require continuous injection, and do not cause adverse reactions due to excessive half-life in livestock; and they are not immunogenic for sows, and will not cause the production of drug-resistant antibodies.
(II) The long-acting recombinant porcine FSH fusion protein and/or porcine FSH protein, and the derived proteins or modified proteins thereof provided by the present invention, have an effective rate of 90% or more in promoting sow estrus, and an effective rate of 85% or more in the treatment of anestrus sows, and achieve an average ovulation rate of about 27 per pig, and an average litter size of about 13 per pig, and have better estrus and superovulation effect than those of PMSG, hFSH-hFc and pFSH-hFc.
(III) The long-acting recombinant porcine FSH fusion protein and/or porcine FSH protein, and the derived proteins or modified proteins thereof provided by the present invention, can also improve the estrus rate of cattle and sheep, and promote the superovulation effect: the number of embryos per cow is about 8.0, and the number of available embryos per cow is about 6.1, which are respectively higher than those of PMSG, hFSH-hFc and pFSH-hFc; and have an effective rate of 90% or more in promoting ewes estrus, which is also better than that of PMSG, hFSH-hFc and pFSH-hFc.
(IV) The long-acting recombinant porcine FSH fusion protein and/or porcine FSH protein, and the derived proteins or modified proteins thereof provided by the present invention, can effectively provide a safe and effective drug for promoting the reproduction rate of animals, especially economic animals.
(V) When applying to the field of animal breeding, the long-acting recombinant porcine FSH fusion protein and/or porcine FSH protein, and the derived proteins or modified proteins thereof have lower immunogenicity and higher biological activity as compared with human FSH, have higher purity and longer half-life as compared with natural porcine pituitary FSH, and have fewer adverse side effects and lower immunogenicity as compared with PMSG.
(VI) The long-acting recombinant porcine FSH fusion protein provided by the present invention can effectively prolong the half-life of porcine FSH, reduce the number of administrations, reduce the immunogenicity, and increase the estrus rate and the ovulation number of pig, cattle, sheep and the like, and does not cause adverse reactions to animals, and can replace porcine pituitary FSH and PMSG in the field of animal breeding.
Brief Description of the Drawings Figure 1 is a diagram showing the SDS-PAGE electrophoresis of pFSH-Fc-1 and pFSH-Fc-2 in Example 1 of the present invention. Wherein, A and C are denatured electropherograms of pFSH-Fc-1 and pFSH-Fc-2, respectively; B and D are non-denatured electropherograms of pFSH-Fc-1 and pFSH-Fc-2, respectively. MK: Protein Marker; 1: Clarified fermentation broth; 2: flow-through solution from Protein A chromatography; 3: solution collected from Protein A chromatography; 4: solution collected from Capto S chromatography; and 5: solution collected from Capto Q chromatography. The structural formula of pFSH-Fc-1 is (pFSHß:pFSHa-L-Fc) , and the structural formula of pFSH-Fc-2 is (pFSHa:pFSHß-L-Fc) .
Figure 2 is a diagram showing the rat ovary of the pFSH-Fc-1, pFSH-Fc-2 and PMSG groups in Example 2 of the present invention. Wherein, 10 IU, 20 IU and 40 IU represent that the rats in the pFSH-Fc-1, pFSH-Fc-2, and PMSG groups were injected with the corresponding drugs in amounts of 10 IU, 20 IU and 40 IU, respectively.
Figure 3 is a diagram showing the ovary of No. 1 superovulated primiparous sows of pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc groups in Example 4 of the present invention.
Specific Modes for Carrying Out the Embodiments The following Examples are intended to illustrate the present invention but are not intended to limit the scope of the present invention. Unless otherwise indicated, the Examples are based on routine experimental conditions, such as Sambrook J & Russell DW, Molecular Cloning: a Laboratory Manual, 2001, or according to the conditions suggested by the manufacturer’s instructions.
The hFSH-hFc and pFSH-hFc described in the following Examples are both obtained by linking ß subunits to hFc, and the construction method is the same as that of pFSH-Fc-2, and comprises: the gene sequences of human FSHa, human FSHß, and human Fc were found after search, after codon optimization, the hFSHa, hFSHß-L-hFc, pFSHa, and pFSHß-L-hFc genes were artificially synthesized, and the hFSHa and hFSHß-L-hFc, pFSHa and pFSHß-L-hFc recombinant plasmids were transferred into 293 cells by transient transfection for expression, and purification was performed to obtain hFSH-hFc and pFSH-hFc.
Example 1: Preparation of pFSH-Fc-1 and pFSH-Fc-2 proteins The GeneBank was searched for gene sequences of porcine FSHa (GenBank NM-214446.1), porcine FSHß (GenBank NM-213875.1) and porcine Fc (GenBank BAE20056). Codon optimization was performed. The nucleotide sequence of pFSHa is represented by SEQ ID NO: 2; the nucleotide sequence of pFSHß is represented by SEQ ID NO: 4; the sequence of pFSHa-L-pFc is represented by SEQ ID NO: 7; and the sequence of pFSHß-L-pFc is represented by SEQ ID NO: 9.
The artificially synthesized pFSHa, pFSHß, pFSHa-L-pFc and pFSHß-L-pFc genes were cloned into the vector pcDNA3.1, respectively. The recombinant vectors of pFSHß and pFSHa-L-pFc, pFSHa and pFSHß-L-pFc were respectively electrotransferred into 293 cells to express pFSH-Fc-1 and pFSH-Fc-2, and the proteins obtained by transient transfection and expression were purified and verified for the activity. After the activity was confirmed, the recombinant vectors of pFSHß and pFSHa-L-pFc, pFSHa and pFSHß-L-pFc were linearized and then electrotransferred into CHO cells to obtain stable cell lines of pFSH-Fc-1 and pFSH-Fc-2.
The stable cells of pFSH-Fc-1 and pFSH-Fc-2 were subjected to fermentation cultivation in a fermentor, and the fermentation broth was subjected to filtration to remove cells and cell debris using two-stage deep bed filtration membrane package, and then filtered through a 0.22 µm filter membrane to obtain clarified fermentation broth. The fermentation broth was firstly purified by Protein A affinity chromatography (MabSelect SuReTM, GE Healthcare): firstly, equilibrated to the baseline with an equilibration solution (50 mM glycine, 0.15 M NaCl, pH 7.2) and then eluted with an eluent (50 mM glycine, pH 3.0), and the eluate was collected. The solution collected from Protein A chromatography was further purified by Capto S cation exchange column (GE Healthcare) chromatography: the collected solution was adjusted to a pH of 6.5 with 1 M NaOH, the conductivity thereof was adjusted to 4.5 to 5.0 ms/cm with water, the collected solution was equilibrated with an equilibration solution (50 mM glycine, pH 6.5), loaded, and the flow-through effluent was collected. The solution collected from Capto S chromatography was finely purified by Capto Q anion exchange column (GE Healthcare) chromatography: the collected solution was adjusted to a pH of 8 with 1 M NaOH, and equilibrated to baseline with an equilibration solution (50 mM glycine pH 8.0), followed by eluting with eluent (50 mM glycine, 1 M KCl, pH 8.0), and the purified protein was collected. The purified protein of interest was subjected to SDS-PAGE gel electrophoresis (Fig. 1).
Example 2: Activity assay of pFSH-Fc-1 and pFSH-Fc-2 proteins The activities of pFSH-Fc-1 and pFSH-Fc-2 were measured using a rat ovarian weight gain method (Steelman-Pohley method). The product of the present invention is intended to be used in place of PMSG in the field of animal breeding. Therefore, the activity of the sample was determined according to the Pharmacopoeia of China 2015 Edition "Serum Gonadotropin Bioassay", with PMSG as a standard. The specific process for implementation was as follows: pFSH-Fc-1 (with an estimated value of specific activity of 10000 U/mg), pFSH-Fc-2 (with an estimated value of specific activity of 10000 U/mg) and PMSG were formulated into three doses of 40 IU (high), 20 IU (medium) and 10 IU (low), respectively.
Female SD (Sprague Dawley) rats of 21-23 day-old, weighted 40-55 g were randomly divided into 9 groups, 6 in each group. Each rat was subcutaneously injected with 0.5 ml of the corresponding drug. After 6 days, the rats were sacrificed, weighed, and dissected, the ovaries were removed, and weighed and the ovary weight was converted into ovary weight per 100 g body weight (Fig. 2). The specific activity of pFSH-Fc-1 was calculated to be about 9600 U/mg using the software of National Institutes for Food and Drug Control, "Pharmacopoeia Bioassay Statistics BS2000", and the specific activity of pFSH-Fc-2 was about 10700 U/mg.
Example 3: Pharmacokinetic Study of pFSH-Fc-1 and pFSH-Fc-2 Proteins Ten SD female rats of about 40 g were randomly divided into two groups: pFSH-Fc-1 group and pFSH-Fc-2 group. The corresponding drug was subcutaneously injected at 20 IU/kg body weight, 100 µl of blood was sampled at 0, 1, 2, 4, 8, 12, 24, 48, 72, 96, 120, and 144 h after administration, respectively, centrifuged at 3000 rpm, and the serum was taken and stored at -80°C for cryopreservation. The contents of pFSH-Fc-1 and pFSH-Fc-2 in the serum were measured using an FSH ELISA kit, and each blood sample was analyzed in triplicate. The half-life of pFSH-Fc-1 was calculated to be 57.2 h using Pksolver software, and the half-life of pFSH-Fc-2 was 63.4 h, both of which were higher than that of natural porcine FSH, and lower than that of PMSG.
Example 4: Use of pFSH-Fc-1 and pFSH-Fc-2 proteins in promoting synchronization of estrus and superovulation in primiparous and multiparous sows 100 primiparous Yorkshire sows and multiparous Yorkshire sows without estrus 2 weeks after weaning, weighed 85-100 kg with the same variety and similar signs were selected, respectively. They were randomly divided into 5 groups: pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc groups; each group was further divided into primiparous sow group and multiparous sow group. 1000 IU of the corresponding drugs were injected into the neck muscles at the back of ear of the donor pigs in each group, and 500 IU of HCG was injected 72 hours later. The estrus of each group of sows was observed after 5 days.
Except for the oestrous No. 1 Yorkshire sow in the primiparous sow group was slaughtered and taken ovary for photographing, the oestrous sows of other groups were bred with the boars of the same variety for 3 times at intervals of 12 h each time. 36 hours after the first breeding, the donor pigs were subjected to surgery for ovums, and the number of ovums ovulated was counted (Fig. 3).
The results were shown in Table 1, The donor pigs in each group had good estrus, and the estrus rate of the primiparous and multiparous sows in the pFSH-Fc-1 group were 90% and 95%, respectively, which were higher than those of the PMSG group (60% and 65%), the hFSH-hFc group (65% and 70%) and the pFSH-hFc group (80% and 85%), and were significantly different from those of the PMSG group and the hFSH-hFc group (P<0.05).
The estrus rates of the primiparous and multiparous sows in the pFSH-Fc-2 group were 100%, and were significantly different from those of the PMSG group and the hFSH-hFc group (P<0.01).
The number of ovums ovulated in each group of sows was higher than that in normal natural oestrous sows (8 to 14/pig), and the average number of ovums ovulated per pig of the primiparous and multiparous sows in the pFSH-Fc-1 group was 27.7 and 27.5, respectively, which were higher than those of the PMSG group (19.8 and 20.2), the hFSH-hFc group (22.1 and 21.6), and the pFSH-hFc group (25.7 and 26.2), and were significantly different from those of the PMSG group and the hFSH-hFc group (P<0.05). The average number of ovums ovulated per pig of the primiparous and multiparous sows in the pFSH-Fc-2 group was 29.9 and 29.1, respectively, which were higher than that of the PMSG group, the hFSH-hFc group and the pFSH-hFc group, and were significantly different from those of the PMSG group and the hFSH-hFc group (P<0.05).
Example 5: Application of pFSH-Fc-1 and pFSH-Fc-2 proteins in increasing litter size of sows 50 primiparous Yorkshire sows with the same variety and similar signs were selected.
They were divided into 5 groups: pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc groups, each group of sows were injected with drugs according to the method of Example 4.
During estrus, the oestrous sows were bred with the boars of the same variety for 3 times at intervals of 12 h each time. The litter size of each group of sows was recorded in detail.
The results were shown in Table 2, the total number of litter sizes of sows in the pFSH-Fc-1 and pFSH-Fc-2 groups (123 and 125) were higher than that of the PMSG group (65), the hFSH-hFc group (68) and the pFSH-hFc group (99), and were significantly different from those of the PMSG and the hFSH-hFc groups (P<0.05). The average number of litter sizes per birth of the pFSH-Fc-1 and pFSH-Fc-2 groups (13.7 and 13.9) were also higher than that of the PMSG group (10.1), the hFSH-hFc group (10.5), and the pFSH-hFc group (12.4).
Table 2: Comparison of pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc on litter sizes of primiparous sows Groups Number of Number of Total number of Average number of sows tested farrowing sows litter sizes litter sizes per birth pFSH-Fc-1 group 10 9 123 13.7±1.25 pFSH-Fc-2 group 10 9 125 13.9±1.19 PMSG group 10 6 65 10.1±1.34 hFSH-hFc group 10 6 68 10.5±1.38 pFSH-hFc group 10 8 99 12.4±1.27 Note: The different capital and lower-case letters of the series superscript on the same column showed significant difference (P<0.05), and the same letter showed non-significant difference (P>0.05).
Example 6: Application of pFSH-Fc-1 and pFSH-Fc-2 proteins in the treatment of anestrus sows 100 anestrus Yorkshire sows without estrus for more than 21 days after weaning were randomly divided into 5 groups: pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc groups. 1000 IU of the corresponding drugs were respectively injected into the neck muscles at the back of ear of the donor pigs in each group, and 500 IU of HCG was injected 72 hours later. The estrus characteristics of sows were observed: such as redness and mucus in the vulva; and standing reflex occurs when the back is pressed. The oestrous sows were bred with boars according to Examples 4 and 5, and the impregnation conditions were recorded.
The results were shown in Table 3. The anestrus sows were sensitive to drug reactions, and the estrus rates of the sows in the pFSH-Fc-1 and pFSH-Fc-2 groups (85% and 90%) were higher than those of the PMSG group (55%), the hFSH-hFc group (65%) and the pFSH-hFc group (75%), and were significantly different from that of the PMSG group (P<0.05). The pregnancy rates of the sows in the pFSH-Fc-1 and pFSH-Fc-2 groups (88.2% and 88.9%) were also higher than those of the PMSG group (63.6%), the hFSH-hFc group (61.5%) and the pFSH-hFc group (73.3%), and the difference was not significant (P>0.05).
Table 3: Comparison of pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc in inducing the estrus of the anestrus sows Groups Number of Number of Estrus rates Pregnancy rates sows tested oestrous pFSH-Fc-1 group 20 17 Abc def 85% (17/20 ) 88.2% (15/17 ) pFSH-Fc-2 group 20 18 Abc def 90% (18/20 ) 88.9% (16/18 ) PMSG group 20 11 55% (11/20 ) 63.6% (7/11 ) hFSH-hFc group 20 13 65% (13/20 ) 61.5% (8/13) pFSH-hFc group 20 15 75% (15/20 ) 73.3% (11/15) Note: The different capital and lower-case letters of the series superscript on the same column showed significant difference (P<0.05), and the same letter showed non-significant difference (P>0.05).
Example 7: Application of pFSH-Fc-1 and pFSH-Fc-2 proteins in promoting superovulation of cows 50 3-6 years old, healthy, disease-free Holstein cows were randomly divided into pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc, and pFSH-hFc groups. Each group of cows was fed 1 kg of concentrative feed based on the original feeding, at the same time, VA, VD and VE were intramuscularly injected. Each donor cow was implanted with progesterone vaginal plug CIDR (containing progesterone 1.56 g/vaginal plug). The day of plugging was recorded as Day 0, each group of donor cows was intramuscularly injected with 1000 IU of the corresponding drug (Day 5), and 0.5 mg of cloprostenol (PG) was injected, and then the plug was removed (Day 10), and the estrus was observed, the mounting of the bull accepted by donor cow shall prevail. The first insemination was performed 12 h after standing estrus, the second insemination was performed 24 h after standing estrus. Embryos were collected on Day 16 by non-surgically washing, and the number of embryos was counted.
The results were shown in Table 4, the superovulation effects of donor cows in each administration group were remarkable (naturally, one cow generates only one embryo at a time), and the average numbers of embryos per cow in the pFSH-Fc-1 group and the pFSH-Fc-2 group (7.9 and 8.7) were higher than that of the PMSG group (5.7), the hFSH-hFc group (6.1), and the pFSH-hFc group (7.3), and were significantly different from those of the PMSG group and the hFSH-hFc group (P<0.05). The average numbers of available embryos per cow in the pFSH-Fc-1 and the pFSH-Fc-2 groups (6.1 and 7.4) were higher than those in the PMSG group (3.5), the hFSH-hFc group (3.9) and the pFSH-hFc group (5.7), and were significantly different from those of the PMSG group and the hFSH-hFc group (P<0.05). The average numbers of unavailable embryos per cow in the pFSH-Fc-1 and pFSH-Fc-2 groups (1.8 and 1.3) were lower than those in the PMSG group (2.2) and the hFSH-hFc group (2.2), and that in the pFSH-Fc-2 group was less than that in the pFSH-hFc group (1.6), and the difference between the pFSH-Fc-2 group and the PMFG group as well as the hFSH-hFc group was significant (P<0.05).
Table 4. Comparison of pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc on superovulation of Holstein cows Groups Average numbers of Average numbers of Average numbers of embryos per cow available embryos per cow unavailable embryos per cow ABc DEf ghi pFSH-Fc-1 group 7.9 ±0.70 6.1 ±0.94 1.8 ±0.40 ABc DEf GHi pFSH-Fc-2 group 8.7 ±0.78 7.4±0.91 1.3 ±0.46 a d g PMSG group 5.7 ±0.64 3.5 ±0.81 2.2 ±0.60 b e h hFSH-hFc group 6.1 ±0.70 3.9 ±0.70 2.2 ±0.87 c f i pFSH-hFc group 7.3±0.95 5.7 ±0.95 1.6±0.70 Note: The different capital and lower-case letters of the series superscript on the same column showed significant difference (P<0.05), and the same letter showed non-significant difference (P>0.05).
Example 8 Application of pFSH-Fc-1 and pFSH-Fc-2 proteins in promoting synchronization of estrus in female goats 75 1.5-3 years old, weighed 30-45 kg, healthy, disease-free goats were randomly divided into pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc groups. The progesterone vaginal plug was implanted on the donor goat at any day in the estrus cycle and the day was recorded as Day 0. Each donor goat was intramuscularly injected with 300 IU of the corresponding drug (Day 10), and then the plug was removed (Day 12). The estrus performance of the female goat was observed, and a teaser goat was used to judge whether the female goat was oestrous. The situations of redness and mucus in the vulva of the female goat and the acceptance of mounting were considered as estrus, and the estrus rate was calculated.
The results were shown in Table 5, the estrus of female goats in each group was obvious, and the estrus rates of female goats in the pFSH-Fc-1 group and the pFSH-Fc-2 group were both 93.3%, which were higher than those of the PMSG group (60%), the hFSH-hFc group (73.3%) and the pFSH-hFc group (80.0%), and were significantly different from that of the PMSG group (P<0.05).
Table 5. Comparison of pFSH-Fc-1, pFSH-Fc-2, PMSG, hFSH-hFc and pFSH-hFc on estrus of female goats Groups Number of Number of Estrus rates female oestrous female goats tested goats 14 Abc pFSH-Fc-1 group 93.3% (14/15 ) 14 Abc 93.3% (14/15 ) pFSH-Fc-2 group PMSG group 15 9 a 60.0% (9/15 ) 11 b hFSH-hFc group 73.3% (11/15 ) 12 pFSH-hFc group 80.0% (12/15 ) Note: The different capital and lower-case letters of the series superscript on the same column showed significant difference (P<0.05), and the same letter showed non-significant difference (P>0.05).
Example 9: Detection of antigenic immunity of pFSH-Fc-1 and pFSH-Fc-2 proteins The antigenic immunities of the pFSH-Fc-1 and pFSH-Fc-2 proteins were detected by detecting the anti-drug antibody (ADA) of the drug in the serum of the sample by using the Bridging-ELISA method. 40 primiparous Yorkshire sows were selected and divided into 4 groups: pFSH-Fc-1 group, pFSH-Fc-2 group, hFSH-hFc group and pFSH-hFc group. 1000 IU of the drugs were injected into the neck muscle at the back of ear of each donor pig, and administered once every three days for a total of 5 weeks (13 times of administration), and the day for the first administration was recorded as Day 0. Blood was collected at the following times: before the first administration (Day -2), before the third administration (Day 6), before the fifth administration (Day 12), and before the sixth to last administration (Day 15, 18, 21, 24, 27, 30, 33 and 36), and the third day after the last administration (Day 39). The blood was centrifuged, the serum was collected, and the OD value of ADA in 490nm the serum was detected in the ELISA plate coated with pFSH-Fc-1, pFSH-Fc-2, hFSH-hFc or pFSH-hFc, respectively. Positive control samples were prepared with anti-pFSH-Fc-1, anti-pFSH-Fc-2, anti-hFSH-hFc or anti-pFSH-hFc rabbit monoclonal antibody diluted with 100% mixed pig serum, respectively; and negative control (N) samples were prepared with serum of a primiparous Yorkshire sow injected with the same amount of PBS buffer. The threshold value (SCP) was used as the judgment value to distinguish whether the test sample was positive or negative. The SCP was calculated to be 1.15 by using JMP® statistical analysis, that is, SCP =1.15 was judged to be positive, and the sample contained ADA; otherwise it was negative and the sample did not contain ADA.
The results were shown in Table 6, the SCPs of the donor pig samples in pFSH-Fc-1 group and pFSH-Fc-2 group were all less than 1.15, and no ADA was detected, indicating that no anti-drug antibody was generated in the Yorkshire sows injected with 1000 IU of pFSH-Fc-1 or pFSH-Fc-2. In the hFSH-hFc group, the SCPs in the serum samples of Nos. 1, 2, 4, 7 and 9 sows were greater than 1.15 on Day 27 and after Day 27 (first detected on Day 27, and last detected on Day 39), and the SCPs in the serum samples of other sows were greater than 1.15 on Day 30 and after Day 30 (first detected on Day 30, and last detected on Day 39), indicating that ADA was detected in all sows in the hFSH-hFc group, i.e., a positive rate of 100%. In the pFSH-hFc group, the SCPs in the serum samples of Nos. 2, 3, 6, 7 and 9 sows were greater than 1.15 on Day 30 and after Day 30 (first detected on Day 30, and last detected on Day 39), the SCPs in the serum samples of Nos. 1, 5, and 8 sows were greater than 1.15 on Day 36 and after Day 36 (first detected on Day 36, and last detected on Day 39), and the SCPs in all serum samples of Nos. 4 and 10 sows were less than 1.15, indicating that ADA was detected in 8 sows in the pFSH-hFc group, i.e., a positive rate of 80%. The above-mentioned results indicate that the Yorkshire sows injected with 1000 IU of hFSH-hFc or pFSH-hFc generate anti-drug antibody.
Table 6. Detection of antigenic immunity of pFSH-Fc-1, pFSH-Fc-2, hFSH-hFc and pFSH-hFc to Yorkshire sows Groups pFSH-Fc-1 pFSH-Fc-2 hFSH-hFc pFSH-hFc Administration dosage 1000IU/pig 1000IU/pig 1000IU/pig 1000IU/pig Time for the first - - Day27 Day30 detection Time for the last - - Day39 Day39 detection Number of individuals 10 10 10 in each group Number of positive 0 0 10 8 individuals Individual positive rate 0% 0% 100% 80% Although the present invention is described in detail using general description and specific embodiments hereinbefore, it is obvious to a person skilled in the art that some modifications or improvements can be made based on the present invention. Hence all these modifications or improvements made on the basis of not deviating from the spirit of the present invention fall into the protection scope claimed in the present invention.
Industrial applicability The present invention provides two long-acting recombinant porcine FSH (follicle-stimulating hormone) fusion proteins, comprising pFSH-Fc-1 and pFSH-Fc-2. a subunit/ß subunit is directly or indirectly fused with a Fc fragment by means of a linking component; the ß subunit/a subunit binds with the a subunit/ß subunit by means of a Van der Waals force or the linking component. The porcine FSH fusion proteins can be prepared by an eukaryotic expression system based on a gene engineering technology. The two porcine FSH fusion proteins provided by the present invention have a good medicinal effect and have a longer half-life period as compared with that of a natural porcine FSH; do not generate an undesirable effect in animals, do not have immunogenicity in the sow, do not cause anti-drug antibody, and can replace pregnant mare serum gonadotropin (PMSG) used in animal breeding production, can effectively promote the reproduction rate of animals, especially economic animals, and have good economic value and application prospects.
Claims (14)
1. A long-acting recombinant porcine FSH fusion protein pFSH-Fc-1, wherein the pFSH-Fc-1 comprises two peptide chains and conforms to the 5 equation (pFSHß:pFSHa-L-Fc) , wherein the pFSHß refers to a ß subunit of the porcine FSH with signal peptide removed; the colon represents that the porcine FSH ß subunit and the a subunit are linked by means of a Van der Waals force; pFSHa refers to an a subunit of the porcine FSH with signal peptide removed; L represents the linking relationship between the pFSHa subunit and the Fc fragment; Fc refers to a Fc fragment 10 of an immunoglobulin; the subscript 2 outside of the parenthesis represents that the pFSH-Fc-1 is a divalent homodimer, wherein the amino sequence of the pFSHa-L-Fc is shown in SEQ ID NO: 6, and the amino sequence of the pFSHß is shown in SEQ ID NO:3. 15
2. A long-acting recombinant porcine FSH fusion protein pFSH-Fc-2, wherein the pFSH-Fc-2 comprises two peptide chains and conforms to the equation (pFSHa:pFSHß-L-Fc) , wherein the pFSHß refers to a ß subunit of the porcine FSH with signal peptide removed; the colon represents that the porcine FSH ß subunit and the a subunit are linked by means of a Van der Waals force; pFSHa refers to an a 20 subunit of the porcine FSH with signal peptide removed; L represents the linking relationship between the pFSHß subunit and the Fc fragment; Fc refers to a Fc fragment of an immunoglobulin; the subscript 2 outside of the parenthesis represents that pFSH- Fc-2 is a divalent homodimer; wherein the amino sequence of the pFSHß-L-Fc is shown in SEQ ID NO: 8, and 25 the amino sequence of the pFSHa is shown in SEQ ID NO:1.
3. An expression cassette comprising a nucleic acid encoding a fusion protein according to any one of claims 1 or 2. 30
4. An expression vector comprising a nucleic acid encoding the fusion protein according to any one of claims 1 or 2.
5. A cloning vector comprising a nucleic acid encoding a fusion protein according to any one of claims 1 or 2. 5
6. A CHO cell for expressing of a fusion protein according to any one of claims 1 or 2, the cell comprising an expression vector of claim 4.
7. A method for preparing a fusion protein according to any one of claims 1 to 2, wherein the method comprises artificially synthesizing genes encoding pFSHa, pFSHß, 10 pFSHa-L-Fc and pFSHß-L-Fc, performing codon optimization, and cloning the optimized genes into eukaryotic expression vectors, respectively; simultaneously transforming the pFSHa recombinant vector and pFSHß-L-Fc recombinant vector into eukaryotic cells, and expressing in eukaryotic cells, and isolating and purifying the target protein; simultaneously transforming the pFSHß recombinant vector and pFSHa- 15 L-Fc recombinant vector into eukaryotic cells, and expressing in eukaryotic cells, and isolating and purifying the target protein.
8. The method according to claim 7, wherein the eukaryotic expression vector is pcDNA3.1, and the eukaryotic cells include 293 and CHO cells.
9. A fusion protein produced according to a method of claim 7 or claim 8.
10. A composition comprising a fusion protein according to any one of claims 1, 2 or 9, an expression cassette according to claim 3, an expression vector according to 25 claim 4, a cloning vector according to claim 5, and/or a CHO cell according to claim 6, together with an acceptable carrier, diluent, or excipient.
11. A method of promoting animal breeding in an animal, wherein the method comprises administering a fusion protein according to any one of claims 1, 2 or 9, and/or 30 a composition according to claim 10 to the animal, wherein the animal is a pig, a cattle, a sheep, a horse or a dog; preferably a pig.
12. A method of synchronizing estrus and superovulation in an animal, the method comprising the step of administering a fusion protein according to any one of claims 1, 2 or 9, and/or a composition according to claim 10, to thereby synchronize estrus and 5 superovulation in the animal, wherein the animal is a pig, a cattle, or a goat.
13. A method of treating a reproductive-related disease in an animal, wherein the method comprises: administering a fusion protein according to any one of claims 1, 2 or 9, and/or a composition according to claim 10 to the animal, wherein the animal is 10 pig, a cattle, a sheep, a horse or a dog; preferably pig.
14. A method of treating anestrus in a pig, the method comprising the step of administering a fusion protein according to any one of claims 1, 2 or 9, and/or a composition according to claim 10, to thereby treat anestrus in the pig. Drawings of the Description
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710833452.1A CN107540748B (en) | 2017-09-15 | 2017-09-15 | Long-acting recombinant porcine FSH fusion protein and preparation method and application thereof |
PCT/CN2017/108854 WO2019051954A1 (en) | 2017-09-15 | 2017-11-01 | Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ760019A NZ760019A (en) | 2023-08-25 |
NZ760019B2 true NZ760019B2 (en) | 2023-11-28 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017431494B2 (en) | Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof | |
CN108676096B (en) | Recombinant porcine FSH-CTP fusion protein and preparation method and application thereof | |
US10519212B2 (en) | Long-acting recombinant follicle-stimulating hormone and use thereof | |
JPH01502669A (en) | Purified platelet-derived growth factor and its purification method | |
EP3482749A1 (en) | Long-acting human follicle-stimulating hormone formulation using immunoglobulin fragment | |
CN103554268B (en) | Long-acting recombinant follicle-stimulating hormone and application thereof | |
WO2014079384A1 (en) | Trophic hormone fusion protein, preparation method and application thereof | |
CN103554269B (en) | Recombinant porcine follicle-stimulating hormone-Fc fusion protein (pFSH-Fc) | |
SK287041B6 (en) | A process for the purification of Luteinizing Hormone (LH) from a sample, recombinant hLH, its use and pharmaceutical composition containing the same | |
EP4339206A1 (en) | Antibody against inhibin and use thereof | |
RU2193599C2 (en) | Receptor of human follicle-stimulating hormone (fsh), dna, vector, method of preparing, pharmaceutical composition | |
NZ760019B2 (en) | Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof | |
CA2929561A1 (en) | Glycoprotein hormone long-acting superagonists | |
JP2899534B2 (en) | Method of inducing superovulation in cattle | |
AU643444B2 (en) | SRIF-related peptides and uses thereof | |
NZ226383A (en) | Method for increasing the number of ova produced during ovulation in ovine, bovine and caprine animals | |
NZ220169A (en) | A method of inducing or increasing ovulation in a non-human animal and veterinary composition therefor | |
CN115991792A (en) | Long-acting recombinant LH fusion protein and preparation method and application thereof | |
JP2000508293A (en) | Novel peptide useful for promoting FSH action | |
CN115975043A (en) | Recombinant follicle stimulating hormone fusion protein | |
WO1993006857A1 (en) | Preparation and use of human trophoblast membrane expressed protein in an anti-fertility vaccine | |
Scaramuzzi et al. | The implications of immunological techniques for the improvement of production efficiency in pigs. | |
WO2007025349A1 (en) | Modulating ovulation and growth rates |